Aims: RapidArc Dynamic (RAD) is a novel radiation therapy solution that leverages dynamic collimation and combines VMAT (Volumetric Modulated Arc Therapy) with static angle modulated ports (STAMPs) in one continuous delivery. This study compares RAD to VMAT for curative nasopharyngeal carcinoma (NPC) cases. Methodology: Twenty T3-4, any N, M0 NPC patients treated with VMAT between July 2019 and July 2023 at our institution were included. Two retrospective RAD (Varian Medical Systems, Palo Alto, USA) plans were created per patient: •RAD1: Single arc with 5 STAMPs •RAD2: 2 arcs with 4 STAMPs per arc Targets, organs at risks (OARs) and complexity metrics were compared. Tumour control probability (TCP) and normal tissue complication probability (NTCP) for xerostomia, dysphagia and mucositis were calculated with published models. TCP and NTCP for RAD1 and RAD2 were compared to VMAT (deltas). Statistical differences were determined by a Wilcoxon signed-rank test (p ≤ 0.05). Blinded RAD and VMAT plans were presented to two practicing radiation oncologists specialising in head and neck with a clinical summary. Reviewers were asked to confirm clinical acceptability (Y/N) and rank the plans from 1 (best) to 3 (worst). Results: Compared with the VMAT plan, RAD1 increased D98% of GTVp_7000 (mean increase 0.82Gy, p=0.01). Compared with VMAT, RAD2 increased D98% of GTVp_7000 (mean increase 0.87Gy, p=0.01) and PTV_7000 (mean increase 0.71Gy, p=0.01). Median TCP delta increased for RAD1 and RAD2 by 0.7% and 0.8% respectively. Xerostomia, Dysphagia and Mucositis median deltas decreased by 2.2%, 1.5% and 1.1% for RAD1 and 2.3%, 1.7% and 1.5% for RAD2. RAD1 and RAD2 approaches were both assessed as acceptable 32/40 compared to only 20/40 VMAT and 32/40 highest ranked plans were either RAD1 or RAD2. Conclusion: RAD improved target coverage and OAR sparing promoting a potential increase of TCP and reduction of NTCP for patients treated for NPC. RAD was preferred over VMAT for most cases.